Q-omics provides the consensus-scored SLX1A profile across patient tissues and cancer cell-line models. SLX1A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLX1A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SLX1A RNA expression shows 6,323 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KIRC, and HNSC as cancer lineages where SLX1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLX1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLX1A survival associations across molecular data types. SLX1A RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLX1A RNA expression–survival associations across cancer types. High SLX1A expression shows unfavorable associations in KIRC, KICH, DLBC, LUAD and ACC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLX1A RNA expression.
This table summarizes SLX1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLX1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLX1A shows higher tumor expression in HNSC, STAD, LUSC, LIHC, COAD and KIRC. The HNSC box plot shows higher SLX1A RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p < 0.001).
This table shows molecular features associated with SLX1A in patient tissues and cancer cell lines. In patient samples, SLX1A shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLX1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
